12:00 AM
 | 
Sep 22, 2008
 |  BC Week In Review  |  Clinical News  |  Regulatory

Mesenchymal precursor cells regulatory update

FDA granted Orphan Drug designation for Angioblast's mesenchymal precursor cell technology to treat insufficient hematopoietic stem cell production in patients...

Read the full 80 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >